ImmunityBio, Inc. (IBRX)

NMS – Real Time Price. Currency in USD

8.12

+0.01 (0.12%)

At close: May 12, 2026, 4:00 PM EDT

8.15

+0.03 (0.37%)

After-hours: May 12, 2026, 7:59 PM EDT

09.05.2026

IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 9, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

09.05.2026

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Who is Involved: ImmunityBio, Inc. (NasdaqGS: IBRX) investors that purchased between January 19, 2026 and March 24, 2026 When to Act: Deadline to file Lead Plaintiff applications is May 26, 2026 Basis: ImmunityBio shares fell on FDA warning letter over cancer therapy claims in advertisement NEW YORK and NEW ORLEANS, May 8, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) ("ImmunityBio" or the "Company"), if they purchased or otherwise acquired the Company's securities between January 19, 2026 and March 24, 2026, inclusive (the "Class Period").

08.05.2026

ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa., May 8, 2026 /PRNewswire/ -- The Law Offices of Howard G.

08.05.2026

IBRX Investor Alert – ImmunityBio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action

SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product.

08.05.2026

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

New York, New York--(Newsfile Corp. - May 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased ImmunityBio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

08.05.2026

IBRX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)

Did you buy IBRX securities between January 19, 2026, and March 24, 202 6? Affected IBRX Investor Summary Who: ImmunityBio, Inc. (NASDAQ: IBRX) What: Securities fraud class action lawsuit filed Class Period: January 19, 2026 through March 24, 2026 Deadline to Seek Lead Plaintiff Status: May 26, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's lead biologic product, Anktiva.

08.05.2026

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for ImmunityBio, Inc. (IBRX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 5/26/20

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
IBRX	BTIG Research	Buy	undefined >> $13	March 12th 2026
IBRX	Piper Sandler	Overweight	undefined >> $5	May 20th 2025
IBRX	H.C. Wainwright	Buy	undefined >> $8	March 6th 2025
IBRX	BTIG Research	Buy	undefined >> $6	January 10th 2025

Press releases

09.05.2026

IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

09.05.2026

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

08.05.2026

ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa., May 8, 2026 /PRNewswire/ -- The Law Offices of Howard G.

08.05.2026

IBRX Investor Alert – ImmunityBio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action

ImmunityBio, Inc. (IBRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ImmunityBio, Inc. (IBRX)

IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

IBRX Investor Alert – ImmunityBio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

IBRX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Videos

No Data

Upgrades / Downgrades

Press releases

IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

IBRX Investor Alert – ImmunityBio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action

IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

IBRX Investor Alert – ImmunityBio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

IBRX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Videos

No Data

Upgrades / Downgrades

Press releases

IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

IBRX Investor Alert – ImmunityBio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action

Search stocks

ImmunityBio, Inc. (IBRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ImmunityBio, Inc. (IBRX)

IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

IBRX Investor Alert – ImmunityBio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

IBRX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Videos

No Data

Upgrades / Downgrades

Press releases

IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

IBRX Investor Alert – ImmunityBio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action

IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

IBRX Investor Alert – ImmunityBio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

IBRX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Videos

No Data

Upgrades / Downgrades

Press releases

IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

IBRX Investor Alert – ImmunityBio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action